Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

which implies that the choice of medical therapy (i.e. whether it is directed at the bladder or the prostate) is often empirical. A role for antimuscarinic agents has been suggested in men with ...

A new clinical trial explores whether targeted steam therapy can offer a less invasive, effective treatment for prostate ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation ...

After men turn 40, it is crucial for them to be regular with their health check-ups, especially when they experience trouble ...

UTIs are also more common in men who have diabetes or are immune ... blood tests and an ultrasound scan of the kidneys and bladder. Treatment for recurrent UTIs in a man might be a regular nightly ...

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive bladder (OAB ... is an important milestone for the men with unresolved symptoms of ...